The U.S. continues to charge significantly higher prices for prescription drugs compared to similarly wealthy countries.

The stock's fall snapped a two-day winning streak.

Several large drugmakers, including Pfizer, Bristol Myers Squibb and Sanofi, increased the list prices of their drugs this month.

Corporate borrowing surged to a record in 2024, up over a third from a year earlier as companies like AbbVie and Cisco looked ...

Neumora Therapeutics' lead candidate, navacaprant, failed to meet primary and secondary endpoints in its Phase 3 KOASTAL-1 ...

In 2023, drug companies launched new medications at prices 35 percent higher than the year before. On January 1, Pfizer ...

Bristol-Myers Squibb (NYSE:BMY – Get Free Report) was the target of unusually large options trading activity on Thursday. Stock investors acquired 296,826 call options on the company. This is an ...

Drugmakers plan to raise US prices on at least 250 branded medications including Pfizer COVID-19 treatment Paxlovid, Bristol ...

Non-transplant salvage therapy for low-risk relapsed/refractory pediatric classical Hodgkin lymphoma (cHL) had high rates of ...

This was the stock's second consecutive day of gains.

Patients on the Tevimbra combo had a 20 percent reduction in risk of death compared to those on chemotherapy alone.

Pharmaceutical companies raised the list prices of at least 250 prescriptions heading into 2025 as major changes to the ...